J Cell Physiol 233(12):94269436 Bobbo VC, Engel DF, Jara CP, Mendes NF, Haddad-Tovolli R, Prado TP et al (2021) Interleukin-6 actions in the hypothalamus protects against obesity and is involved in the regulation of neurogenesis
While these symptoms often reflect the medication's mechanism of action combined with altered biliary physiology, persistent or severe abdominal pain, vomiting, or signs of jaundice may indicate complications requiring urgent medical attention and discontinuation of semaglutide
GLP-1 drugs like semaglutide and tirzepatide are typically self-injected and fall under pharmacy benefits, but many payers have historically only covered them for diabetes, not obesity ( [3] ) ( [4] )
It is not intended for human or veterinary use and must not be used as an injectable product, medication, or for any clinical application